**İbrahim Benter BS, PhD, FAHA(Fellow of American Heart Association)**

**Email:** ifbenter@gmail.com | **Telephone:** +90 533 826 4145 |

**Personal Information** **Name – Ibrahim BENTER, BS / PhD / FAHA (Fellow of American Heart Association)**

 **Address – Lefkoşa, Cyprus**

 **Telephone – Mobile: +90 533 826 4145**

 **Date/Place of Birth – 1962/Cyprus**

**Career highlights 1.Published 80+ papers in top journals of Medicine.**

**2.Showed that angiotensin-( 1-7 ) could be developed into a drug for treatment of cardiovascular and inflammatory diseases.**

**3.Papers have been cited more than six thousand times (6500+),**

**(H-index=40)**

**4.Part of the team that revised the curriculum at Faculty of Medicine at Kuwait University into an integrated curriculum that involves problem based learning.**

**5.Received numerous awards for teaching and research in USA and Kuwait.**

**6. Won and managed more than $5 million as Research Grants.**

**Education Türk Maarif Koleji, Nicosia – Cyprus (1974-1979)**

**Loughborough Technical College, Loughborough - UK**

 **GCE A Levels: Physics, Chemistry, Biology (1979-1981)**

**University of Florida, B.S., Faculty of Arts & Sciences**

 **Gainesville, Florida – USA, Major: Chemistry (1982-1985)**

 **New York Medical College, Graduate Student, New York - USA**

**Major: Pharmacology, transferred to the Ohio State University with advisor Prof Patrick E. Ward (1986-1988)**

**The Ohio State University, Ph.D., Columbus, Ohio - USA**

**Department of Pharmacology, College of Medicine,**

**Major: Pharmacology (1988-1991)**

**University of Dundee, Masters Course in Medical Education,**

**Centre for Medical Education (2004–2005)**

Contents

[**Professional Experience 3**](#_Toc341612821)

[**Awards and Honors 4**](#_Toc341612822)

[**Editorial Services 5**](#_Toc341612823)

[**Professional Affiliations 5**](#_Toc341612824)

[**Committee Activities 5**](#_Toc341612825)

[**Teaching Summary 8**](#_Toc341612826)

[**Research Activities 11**](#_Toc341612827)

[**Publications 16**](#_Toc341612828)

[**Abstracts 28**](#_Toc341612829)

Professional Experience **University of Florida, Gainesville, Florida – USA**

 **Teaching Assistant, Department of Chemistry ( 1984 - 1985 )**

 **New York Medical College, New York – USA**

**Research & Teaching Assistant, Departments of Physiology and Pharmacology ( 1986 - 1988 )**

**The Ohio State University, Columbus, Ohio – USA**

**Teaching & Research Assistant, Department of Pharmacology**

**College of Medicine (1988 - 1991 )**

**The Cleveland Clinic Foundation, Cleveland, Ohio – USA**

**Research Fellow, Department of Brain and Vascular Research (1991 - 1992 )**

**Wake Forest University School of Medicine, North Carolina – USA**

**Research Scientist, Hypertension Research Center (1992 - 1994 )**

 **University of Tennessee, College of Medicine, Tennesse – USA**

**Adjunct Professor of Pharmacology, ( 1994 – 2000 )**

**Southern College of Optometry, Memphis, Tennesse – USA**

**Assistant Professor of Pharmacology ( 1994 – 1999 )**

**Associate Professor of Pharmacology ( Jan 2000 – May 2000 )**

**Kuwait University, Dept of Pharmacology, Faculty of Medicine Associate Professor ( June 2000 – March 2008 )**

**Professor (March 2008 – 2014 )**

**Chairman ( May 2002 – June 2009 )**

**Cardiff University, School of Pharmacy, Cardiff, UK**

**Visiting Professor, Centre for Genome-Based Therapeutics, ( May 2005 – September 2005 and May 2007 – September 2007)**

**Oxford University, Oxford, UK**

**Visiting Professor, Dept of Pharmacology,**

**( August 2012 – July 2013 )**

 **Cyprus Evkaf Administration, Nicosia, Cyprus**

 **Director (2014-2023)**

 **Eastern Mediterrenean University, Faculty of Medicine, Cyprus**

 **Professor (2014-present)**

Awards and Honors **1989 - First Prize: Bennett Graduate Research Society, Fifth Annual Research Day the Ohio State University, College of Medicine, USA**

**1990 - First Prize: Bennett Graduate Research Society, Fifth Annual Research Day the Ohio State University, College of Medicine, USA**

**1994 - First Prize: Resident’s & Fellows Research Day, Wake Forest University School of Medicine**

**1994 - American Society of Hypertension Travel Award**

**1996 - New Investigator Award, American Heart Association, USA**

**1998 - Elected Fellow of High Blood Pressure Research Council American Heart Association, USA**

**1999 - Recognition for serving as a mentor for the students in the 1999 Young Memphis Scholars Program at University of Tennessee Memphis**

**2000 - Teacher of the Year Award, Southern College of Optometry, USA**

**2002 - Best Teacher Award, Kuwait University Medical Student Association**

**2003 - Best Teacher Award, Kuwait University Medical Student Association**

**2004 - Best Basic Medical Science Research Award 9th Health Sciences Centre Poster Conference, Kuwait University**

**2005 - Best Basic Medical Science Research Award 10th Health Sciences Centre Poster Conference, Kuwait University**

**2006 - Best Basic Medical Science Research Award 11th Health Sciences Centre Poster Conference, Kuwait University**

**2004 - Best Teacher Award Kuwait University Medical Student Association Faculty of Medicine, Kuwait University, Kuwait**

**2005 - Best Teacher Award Kuwait University Medical Student Association Faculty of Medicine, Kuwait University, Kuwait**

**2006 - Best Teacher Award Kuwait University Medical Student Association Faculty of Medicine, Kuwait University, Kuwait**

**2006 - Elected member of American Physiological Society**

**2008 - Best Basic Medical Science Research Award 13th Health Sciences Centre Poster Conference, Kuwait University**

**2012 - Best Undergraduate Basic Medical Science Research Award**

**17th Health Sciences Centre Poster Conference, Kuwait University**

Editorial Services **1. Frontiers in Physiology - Review Editorial Board Member**

**2. Referee Editor in the following journals: Hypertension, Cardiovascular Research, Journal of Pharmacology & Experimental Therapeutics, Journal of Drug Targeting, American Journal of Hypertension, British Journal of Pharmacology**

Professional Affiliations **1. The American Society of Pharmacology & Experimental Therapeutics**

**2. The American Society of Hypertension**

**3. European Society of Hypertension**

**4. High Blood Pressure Research Council, American Heart**

**Association**

**5. American Physiological Society**

**6. International Society of Hypertension**

Committee Activities **Southern College of Optometry, Memphis, TN – USA. Coordinator of Medical Pharmacology course ( 1994 - 2000 )**

**Southern College of Optometry, Memphis, TN – USA.** **Coordinator of Medical Pharmacology Examination Committee ( 1994 - 2000 )**

**Southern College of Optometry, Memphis, TN – USA.** **Coordinator of Physiology Laboratory course ( 1994 - 2000 )**

**Southern College of Optometry, Memphis, TN – USA.** **Member of the University Research Committee ( 1997 - 2000 )**

**Southern College of Optometry, Memphis, TN – USA.** **Member of the University Awards Committee ( 1998 - 2000 )**

**Southern College of Optometry, Memphis, TN – USA.** **Member of the Faculty Affairs Committee ( 1998 - 2000 )**

**Southern College of Optometry, Memphis, TN – USA.** **Organizer of workshops for training junior faculty in writing research manuscripts ( 1996 - 2000 )**

**Southern College of Optometry, Memphis, TN – USA** **Organizer of Hypertension Journal Club ( 1996 - 2000 )**

**University of Tennessee, Memphis, TN – USA.** **Trained students in the Young Memphis Scholars Program at University of Tennessee Memphis where high school students conducted summer research ( 1998 - 2000 )**

**Southern College of Optometry, Memphis, TN – USA.** **Director of Preventative Health ( 1999 - 2000 )**

**Kuwait University, Faculty of Medicine** - **Member of Examination Committee at Department of Pharmacology & Toxicology ( 2000 - 2012 )**

**Kuwait University, Faculty of Medicine** - **Coordinator of Medical/Dental Pharmacology Course at Department of Pharmacology & Toxicology ( 2001 - 2004 )**

**Kuwait University** - **Member of Central Organizing Committee for the International Conference: Applications of Molecular Biology in Modern Medicine ( 2004 )**

**Kuwait University, Faculty of Medicine** - **Member of Medical Research Council ( 2001 - 2007 )**

**Commitee Activities ( cont.) Kuwait University, Faculty of Medicine** - **Member of New Medical Curriculum Phase II Review Group ( 2006 - 2009 )**

**Kuwait University, Faculty of Medicine** - **Member of New Medical Curriculum Phase II Examination Committee ( 2006 - 2009 )**

**Kuwait University, Faculty of Medicine** - **Chairman, Department of Pharmacology and Toxicology ( 2002 - 2009 )**

**Kuwait University, Faculty of Medicine** - **Member of TDM/Toxicology Service Committee Dept of Pharmacology & Toxicology ( 2003 - 2009 )**

**Kuwait University, Faculty of Medicine** - **Member of Departmental Appointments and Promotion Committee ( 2002 - 2009 )**

**Kuwait University, Faculty of Medicine** - **Chairman of the Organizing Committee of the 11th Annual Health Sciences Poster Conference, Invited Nobel Laureate Sir Martin Evans who discovered stem cells ( 2005 - 2006 )**

**Kuwait University, Faculty of Medicine** - **Chairman of Departmental Scholarship Committee ( 2003 - 2009 )**

**Kuwait University, Faculty of Medicine** - **Member of Graduate Comprehensive Exam Committee ( 2004 - 2008 )**

**Kuwait University, Faculty of Medicine** - **Director of TDM/Toxicology Service laboratory at Department of Pharmacology & Toxicology ( 2006 - 2009 )**

**Kuwait University, Faculty of Medicine** - **Member of the Organizing Committee of International Conference: Therapeutic Drug Monitoring-Clinical Toxicology Meeting ( 2009 )**

***Dr. Michael Greenberg, President of American Academy of Clinical Toxicology, Temple University Program Director of Medical Toxicology; Chief of Division of Medical Toxicology; Professor of Emergency Medicine, was invited.***

***I initiated collaboration with Dr Greenberg to establish the first Toxicology Center in Kuwait that would work in coordination with the Philadelphia Temple University Toxicology Center.***

**Kuwait University, Faculty of Medicine** - **Representative to Faculty Scientific Affairs Committee ( 2009 - Present )**

**Kuwait University, Faculty of Medicine** - **Coordinator of Department Research Committee ( 2009 - 2012 )**

**Kuwait University, Faculty of Medicine** - **Member of Department Graduate Program Committee ( 2009 - 2012 )**

**Commitee Activities ( cont.) Kuwait University, Faculty of Medicine** - **Coordinator of Molecular Pharmacology course ( 2009 - 2012 )**

**Kuwait University, Faculty of Medicine** - **Coordinator of Experimental Techniques course ( 2009 - 2012 )**

**Kuwait University, Faculty of Medicine** - **Module representative for Reproductive/Renal/Breast Module ( 2009 - 2012 )**

**Kuwait University, Faculty of Medicine** - **Member of Committee to select chairman of Dept of Anatomy ( 2012 )**

**Kuwait University, Faculty of Medicine** - **Chairman, Academic Accreditation Committee ( 2011 - 2014 )**

**Kuwait University, Faculty of Medicine** - **Member of Committee to select chairman of Dept of Biochemistry ( 2012 )**

Teaching Summary **Southern College of Optometry and College of Medicine, University of Tennessee - USA**

**Teaching responsibilities at undergraduate level were:**

**1. Drug-Receptor Interactions**

**2. Pharmacodynamics I-IV**

**3. Pharmacokinetics I-V**

**4. Principles of Autonomic Nervous Sytem I-VI**

**5. Cardiovascular System I-V**

**6. Endocrine Pharmacology I-IV**

**7. Chemotherapy I-VII**

**8. Neuropharmacology I-V**

**Teaching responsibilities at graduate level were:**

**Cardiovascular system lectures were given at the graduate level at College of Medicine, University of Tennessee.**

**Faculty of Medicine, Kuwait University - Kuwait**

**Teaching responsibilities at undergraduate level given for Medical, Dental and Pharmacutical students were:**

**1. Introduction to Pharmacology**

**2. Pharmacokinetics I – drug absorption**

**3. Pharmacokinetics II – drug distribution**

**4. Pharmacokinetics III – drug metabolism I**

**5. Pharmacokinetics IV – drug metabolism II**

**6. Pharmacokinetics V – drug excretion**

**7. Pharmacokinetics VI**

**8. Pharmacokinetics VII**

**9. Pharmacokinetics Tutorial**

**10. Pharmacogenomics**

**11. Polypeptides**

**12. Treatment of hypertension – I**

**13. Treatment of hypertension – II**

**14. Treatment of cardiac arrhythmias**

**15. Introduction antimicrobials**

**16. Antibacterials – I**

**17. Antibacterials – II**

**18. Antibacterials – III**

**19. Antibacterials – IV**

**20. Antibacterials – V**

**21. Antibacterials – VI**

**22. Antibacterials - VII**

**23. Case study group discussions (autonomic nervous system, cardiovascular pharmacology, autacoids, eicosanoids, NSAIDs, hormones, antibacterials, drug interactions, toxicology).**

**Undergraduate Problem Based Learning (PBL) Facilitator for the following modules: Foundation, Cardiovascular, Reproduction/Renal/Breast, Endocrine, CNS, Respiratory.**

**Teaching responsibilities at graduate level given for Medical, Dental and Pharmacutical students were:**

**1. Cardiovascular Pharmacology**

**2. Molecular Pharmacology**

**3. Molecular Medicine**

**4. Principles of Pharmacology I and II**

**5. Experimental Techniques**

**In addition, teaching responsibilities also included coordination the following graduate courses:**

1. **Molecular Pharmacology**
2. **Experimental Techniques**

**Graduate Student Supervision Summary:**

**2003 - Thesis Committee member, Lamia Hoteit, awarded M.Sc. in Physiology.**

**2005 - Thesis Supervisor, Nisreen G. Hares, awarded M.Sc. in Pharmacology & Toxicology.**

**2006 - Thesis Supervisor, Fatma M. Al-Saleh, awarded M.Sc. in Pharmacology & Toxicology.**

**2006 - Thesis Committee, Osama Rashid, awarded M.Sc. in Biochemistry.**

**2008 - Thesis Supervisor, Mohammed Al-Mulla awarded M.Sc. in Physiology**

**2008 - Thesis supervisor: Batool Makki, awarded MSc in Pharmacology & Toxicology**

**2010 - Thesis Supervisor, Najla Marafie awarded MSc in Pharmacology & Toxicology**

**2010 - Thesis Co-supervisor: Omama Al-Farisi awarded MSc in Pharmacology & Toxicology**

**2010 - Thesis Supervisor, Haifa’a J. Al-Otaibi awarded MSc in Pharmacology & Toxicology**

**2011 - Thesis Supervisor, Bashayer Baroon awarded MSc in Pharmacology & Toxicology**

**2012 - Thesis Supervisor, Amal Al-Sumairi awarded MSc in Pharmacology**

**2012 - Thesis Committee, Fatma Al-Rashidi awarded MSc in Molecular Biology**

Research Activities **Research Areas of Interest and Track record**

**Treatment of hypertension- and diabetes-induced cardiovascular dysfunction.**

**Characterizing the role of Angiotensin-(1-7), EGFR and that of cytochrome P450 metabolites of arachidonic acid in the development/treatment of hypertension- and diabetes-induced organ dysfunction (cardiac-, vascular- and erectile-dysfunction).**

**My research group has a long track history in the study of the role of Angiotensin–(1-7) and that of cytochrome P450 metabolites of arachidonic acid in cardiovascular diseases including hypertension, diabetes and more recently in erectile dysfunction. Indeed, my research group was the first to show that:**

**1.Angiotensin-(1-7) can decrease blood pressure.**

**Benter IF, et al. Cardiovascular actions of angiotensin-(1-7). Peptides 1993; 14(4):679-84.**

**2.Ang-(1-7) produces vasodilation by acting through a unique (non-AT1/AT2) receptor & release of prostaglandins.**

**Benter IF, et al. Cardiovascular actions of angiotensin-(1-7). Peptides 1993; 14(4):679-84.**

**3. Ang-(1-7) has anti-hypertensive effects.**

**Benter IF, et al. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. American Journal of Physiology 1995; 269:H313-319.**

**Benter IF, et al. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME.American Journal of Physiology Heart Circ Physiol. 2006; 290(2):H684-H691.**

**4.Ang-(1-7) can prevent diabetes-induced cardiovascular dysfunction.**

**Benter IF, et al. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. American Journal of Physiology Heart Circ Physiol. 2007; 292(1):H666-H672.**

**5.Ang-(1-7) can inhibit oxidative stress.**

**Benter IF, et al. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. American Journal of Nephrology 2008; 28(1):25-33.**

**6.Ang-(1-7) has beneficial effects on corpus cavernosum.**

**Yousif MH, Kehinde EO, Benter IF. Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum. Pharmacological Research 2007; 56(3):209-216.**

**7. Ang-(1-7) can inhibit inflammation.**

**Al-Maghrebi M, Benter IF, Diz DI. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacological Research 2009;59:263-268.**

**8.Characterization of the role of CYP P450 metabolites of AA in regulation of corporal smooth muscle tone in diabetic and older rats.**

**Yousif MH & Benter IF. Vascular Pharmacology 2007; 47:281-287.**

**9.Characterization of the role of CYP P450 metabolites of AA in regulation of cardiac and vascular function in diabetic rats.**

**Yousif MH, Benter IF, Roman RJ. Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Autonomic & Autacoid Pharmacology 2009; 29:33-41. Yousif MH, Benter IF, et al. Role of 20-hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes. Autonomic & Autacoid Pharmacology 2009; 29:1-12.**

**Research/teaching laboratories established at Kuwait University Faculty of Medicine:**

* **Established Cardiovascular Research Laboratory, Department of Pharmacology and Toxicology**
* **Established Departmental Shared Facility laboratory, Department of Pharmacology and Toxicology**
* **Established Molecular Core Facility laboratory, Department of Pharmacology and Toxicology**
* **Established TDM/Toxicology Service laboratory, Department of Pharmacology and Toxicology**

**Research Collaborations**

**1. Debra I. Diz, PhD, FAHA**

**Professor and Director, Hypertension & Vascular Research Center**

**Professor, General Surgery, Division of Surgical Sciences**

**Professor, Department of Physiology & Pharmacology**

**Wake Forest University School of Medicine, North Carolina, USA**

**2. Antony Galione FMedSci**

**Professor and Head of Pharmacology, Oxford University**

**Department of Pharmacology**

**Oxford University**

**Oxford, UK**

**3. J. Russel Falck, PhD**

**Robert A. Welch Distinguished Chair in Chemistry**

**Professor of Pharmacology**

**Professor of Biochemistry**

**University of Texas Southwestern Medical Center**

**Dallas, USA**

**4. Kafait U. Malik, PhD**

**Professor, Dept of Pharmacology, College of Medicine**

**University of Tennessee**

**Memphis, USA**

**5. Drs. Mariam Yousif, Gursev Dhaunsi, Waleed Reno, Marion Turcani, Issam Francis, Elijah Kehinde**

**Departments of Pharmacology, Physiology, Anatomy, Pathology, Medicine, Surgery, Faculty of Medicine, Kuwait University.**

**6. Prof Saghir Akhtar, Qatar University College of Medicine.**

**Research Projects in Kuwait**

**1. Characterization of signaling pathways in hypertension using microarray-based global gene expression profiling.**

**Funding Agency: Kuwait University Research Administration**

**Project number: RM02/03 Total budget: $235,000.00 USD**

**Role in the project: Principle Investigator**

**Status: Completed Rated: Excellent**

**2. Role of endogenous Angiotensin-(1-7) in preventing diabetes-induced cardiac dysfunction.**

**Funding Agency: Kuwait University Research Administration**

**Project No: YM 15/07 Total budget: $20,000.00 USD**

**Role: Principal investigator**

**Status: Completed Rated: Excellent**

**3. Understanding the role of epidermal growth factor signaling in angiotensin-(1-7)-mediated cardioprotection in diabetes.**

**Funding Agency: Kuwait University Research Administration**

**Project No: YM 06/08 Total budget: $20,000.00 USD**

**Role: Co-Investigator**

**Status: Completed Rated: Excellent**

**4. Mechanisms involved in anti-hypertensive effects produced by inhibitors of Ras GTPase/MAP kinase in deoxycorticosterone-salt-induced hypertension.**

**Funding Agency: Kuwait University Research Administration**

**Project number: MR03/00 Total budget: $15,000.00 USD**

**Role in the project: Co-Investigator**

**Status: Completed Rated: Excellent**

**5. Characterization of the effects of preconditioning and Ras-GTPase inhibition on left ventricular gene expression profiles in the globally ischemic heart.**

**Funding Agency: Kuwait University Research Administration**

**Project number: RM01/04 Total budget: $22,000.00 USD**

**Role in the project: Co-Investigator**

**Status: Completed Rated: Excellent**

**6. Maintenance, upgrade, and running cost funding for existing shared lab facility in the faculty of Medicine.**

**Funding Agency: Kuwait University Research Administration**

**Project number: GM01/01 Total budget: $450,000.00 USD**

**Role in the project: Co-Investigator**

**Status: ongoing**

**7. Effect of acute inhibition of soluble epoxide hydrolase in prevention of hypertension- induced vascular dysfunction.**

**Funding Agency: Kuwait University Research Administration**

**Project number: (MR 03/06) Total budget: $22,000.00 USD**

**Role in the project: Co-Investigator**

**Status: Completed Rated: Excellent**

**8. Effects of acute Ras-GTPase mediated signaling pathway inhibition in the ovine model of acute regional myocardial ischemia.**

**Name of the funding institute: KFAS**

**Project number: XK04/05 Total budget: $125,000.00 USD**

**Role in the project: Co-investigator**

**Status: pending**

**9. Understanding the role of epidermal growth factor signaling in angiotensin-(1-7) mediated cardioprotection in diabetes.**

**Funding Agency: Kuwait University Research Administration**

**Project number: YM09/08 Total budget: $15,000.00 USD**

**Role in the project: Principal Investigator**

**Status: Completed Rated: Excellent**

**10. Does angiotensin-(1-7) prevent diabetes-induced vascular dysfunction via inhibition of epidermal growth factor receptor signaling?**

**Funding Agency: Kuwait University Research Administration**

**Project number: YM06/08 Total budget: $20,000.00 USD**

**Role in the project: Co-Investigator**

**Status: ongoing**

**11. Characterization of angiotensin-(1-7)-mediated cardioprotection in diabetes.**

**Funding Agency: Kuwait University Research Administration**

**Project No. (YM 15/07) Total budget: $145,000.00 USD**

**Role: Principal investigator**

**Research Team: Dr. G. Dhaunsi (Co-Investigator), Batool Makki (M.Sc Graduate student).**

**Status: Completed Rated: Excellent**

**12. Impact of pregnancy on the pharmacokinetics of topiramate in rabbits.**

**Funding Agency: Kuwait University Research Administration**

**Project number: YM11/08 Total budget: $15,000.00 USD**

**Role in the project: Principal Investigator**

**13. Studies on the signalling mechanisms that contribute to the effects of angiotensin-(1-7) in diabetes-induced erectile dysfunction.**

**Funding Agency: Kuwait University Research Administration**

**Research Project No. (MR 04/09) Total budget: $230,000.00 USD**

**Role: Co-Investigator**

**Research Team: Drs. M. Yousif (P.I), S. Akhtar & G. Dhaunsi (Co-Investigators).**

**Postdoctoral researchers trained**

**1. Dr. N. A. Karzoun. (1997 - 1999) University of Tennessee, School of Medicine - U.S.A.**

**2. Dr. Ahmed H. Abul (2007-2009) Department of Pharmacology, Faculty of Medicine – Kuwait University**

**3. Dr Ahmed Al-Turki (2009-present) Department of Pharmacology, Faculty of Medicine – Kuwait University**

Publications **Journal Articles**

**1. Stier CT Jr, Benter IF, Levine S. Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats. Stroke 19:1145-1150, 1988.**

**2.Stier CT Jr, Benter IF, Ahmad S, Zuo HL, Selig N, Roethel S, Levine S, Itskovitz HD. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats.**

**Hypertension 13:115-121, 1989.**

**3.Benter IF, Hirsh EM, Tuchman AJ, Ward PE. N-terminal degradation of low molecular weight opioid peptides in human cerebrospinal fluid. Biochemical Pharmacology 40:465-472, 1990.**

**4.Ward PE, Benter IF, Dick L, Wilk S. Metabolism of vasoactive peptides by plasma and purified renal aminopeptidase M.**

**Biochemical Pharmacology 40:1725-1732, 1990.**

**5.Wang LH, Ahmad S, Benter IF, Chow A, Mizutani S, Ward PE. Differential processing of substance P and neurokinin A by plasma dipeptidyl (amino) peptidase IV, aminopeptidase M and angiotensin converting enzyme.**

**Peptides 12:1357-1364, 1991.**

**Publications ( cont.) 6.Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin(1-7). Peptides 14:679-684, 1993.**

**7.Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats.**

**American Journal of Physiology 269:H313-H319, 1995.**

**8.Benter IF, Diz DI, Ferrario CM. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7).**

**Hypertension 26:1138-1144, 1995.**

**9.Muthalif MM, Benter IF, Uddin MR, Malik KU. Calcium/calmodulin-dependent protein kinase IIalpha mediates activation of mitogen-activated protein kinase and cytosolic phospholipase A2 in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells.**

**Journal of Biological Chemistry 271:30149-30157, 1996.**

**10. Benter I.F. Significance of angiotensin-(1-7) in treatment of hypertension. New Journal of Medicine 14:7-9, 1997.**

**11. Benter I.F., and Ward P.E. Enkephalin metabolism by human plasma and endothelial peptidases. Pharmacology Reviews and Communications 9:99-106, 1997.**

**12. Benter I.F., Mizutani S., Tomada Y. and Ward P.E. Metabolism of angiotensin peptides and analogs by human plasma and vasculature. Turkish Journal of Medical Sciences 27:113-119, 1997.**

**13. Diz DI, Fantz DL, Benter IF, Bosch SM. Acute depressor actions of angiotensin II in the nucleus of the solitary tract are mediated by substance P. American Journal of Physiology 273:R28-R34, 1997.**

**14. Muthalif MM, Benter IF, Uddin MR, Harper JL, Malik KU. Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. Journal of Pharmacology and Experimental Therapeutics 284:388-398, 1998.**

**Publications ( cont.) 15. Uddin MR, Muthalif MM, Karzoun NA, Benter IF, Malik KU. Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling. Hypertension 31:242-247, 1998.**

**16. Zagvazdin Y, Reiner A, Benter IF. Central nervous system is not involved in initiation of the pressor effect of 7-nitroindazole in urethane-anesthetized rats. Hypertension 31:719-721, 1998.**

**17. Zagvazdin Y, Reiner A, Benter IF. How selective is 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase? Anesthesia and Analgesia 86:679-680, 1998.**

**18. Muthalif MM, Benter IF, Karzoun N, Fatima S, Harper J, Uddin MR, Malik KU. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proceedings of National Academy of Sciences USA 95:12701-12706, 1998.**

**19. Muthalif MM, Benter IF, Khandekar Z, Gaber L, Estes A, Malik S, Parmentier JH, Manne V, Malik KU. ontribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to eoxycorticosterone-salt-induced hypertension.**

**Hypertension 35:457-463, 2000.**

**20. Muthalif MM, Parmentier JH, Benter IF, Karzoun N, Ahmed A, Khandekar Z, Adl MZ, Bourgoin S, Malik KU. Ras/mitogen-activated protein kinase mediates norepinephrine-induced phospholipase D activation in rabbit aortic smooth muscle cells by a phosphorylation-dependent mechanism. Journal of Pharmacology and Experimental Therapeutics 293:268-274, 2000.**

**21. Muthalif MM, Karzoun NA, Gaber L, Khandekar Z, Benter IF, Saeed AE, Parmentier JH, Estes A, Malik KU. Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension 36:604-609, 2000.**

**22. Muthalif MM, Karzoun NA, Benter IF, Gaber L, Ljuca F, Uddin MR, Khandekar Z, Estes A, Malik KU. Functional significance of activation of calcium/calmodulin-dependent protein kinase II in angiotensin II--induced vascular hyperplasia and hypertension. Hypertension 39:704-709, 2002.**

**23. Yousif MH, Benter IF, Akhtar S. Inhibition of calcium/calmodulin-dependent protein kinase II normalizes diabetes-induced abnormal vascular reactivity in the rat perfused mesenteric vascular bed. Autonomic & Autacoid Pharmacology 23:27-33, 2003.**

**24. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. Journal of Drug Targeting 11:311-323, 2003.**

**25. Petch AK, Sohail M, Hughes MD, Benter I, Darling J, Southern EM, Akhtar S. Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides. Biochemical Pharmacology 66:819-30, 2003.**

**Publications ( cont.) 26. Beale G, Hollins AJ, Benboubetra M, Sohail M, Fox SP, Benter I, Akhtar S. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activityof siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. Journal of Drug Targeting 11:449-456, 2003.**

**27. Yousif MH, Benter IF, Abraham S, Akhtar S. Inhibition of Ras-GTPase improves diabetes-induced abnormal vascular reactivity in the rat perfused mesenteric vascular bed. Medical Principles and Practice 13:57-62, 2004.**

**28. Benter IF, Juggi JS, Khan I, Akhtar S. Inhibition of Ras-GTPase, but not tyrosine kinases or Ca2+/calmodulin-dependent protein kinase II, improves recovery of cardiac function in the globally ischemic heart. Molecular and Cellular Biochemistry 259:35-42, 2004.**

**29. Hussain M, Shchepinov M, Sohail M, Benter IF, Hollins AJ, Southern EM, Akhtar S. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. Journal of Controlled Release 99:139-55, 2004.**

**30. Khan A, Benboubetra M, Sayyed PZ, Wooi Ng K, Fox S, Beck G, Benter IF, Akhtar S. Sustained Polymeric Delivery of Gene Silencing Antisense ODNs, siRNA, DNAzymes and Ribozymes: In Vitro and In Vivo Studies. Journal of Drug Targeting 12:393-404, 2004.**

**31. Benter IF, Juggi JS, Khan I, Yousif MH, Canatan H, Akhtar S. Signal transduction mechanisms involved in preconditioning: Role of Ras-GTPase, Ca2+/calmodulin-dependent protein kinase II and epidermal growth factor receptor. Molecular and Cellular Biochemistry 268:175-183, 2005.**

**32. Yousif MH, Benter IF, Akhtar, S. The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Autonomic and Autacoid Pharmacology 25: 69-78, 2005.**

**33. Benter IF, Francis I, Khan I, Cojocel C, Juggi JS, Yousif MH, Canatan H, Alshawaf EH, Akhtar S. Signal transduction involving Ras-GTPase contributes to development of hypertension and end-organ damage in spontaneously hypertensive rats-treated with L-NAME. Pharmacological Research 52(5): 401-12, 2005.**

**34. Benter IF, Yousif MH, Hollins AJ, Griffiths SM, Akhtar S. Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. Journal of Vascular Research 42: 284-291, 2005.**

**35. Benter IF, Yousif MH, Canatan H, Akhtar, S. Inhibition of Ca2+/calmodulin-dependent protein kinase II, Ras-GTPase and 20-hydroxyeicosatetraenoic acid attenuates diabetes-induced vascular dysfunction in the rat carotid artery. Pharmacological Research 52: 252-257, 2005.**

**36. Benter IF, Yousif MH, Griffiths SM, Benboubetra M, Akhtar S. Epidermal growth factor receptor tyrosine kinase-mediated signaling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. British Journal of Pharmacology 145: 829-836, 2005.**

**37. Benter IF, Francis I, Cojocel C, Juggi JS, Yousif MH, Halit Canatan. Contribution of cytochrome P450 metabolites of arachidonic acid to hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Autonomic Autacoid Pharmacology 25: 143-154, 2005.**

**38. Yousif MHM, Benter IF, Hares N, Canatan H and Akhtar S. Phosphoinositide 3-kinase mediated signalling contributes to development of diabetes-induced abnormal vascular reactivity of rat carotid artery. Cell Biochemistry & Function 24:13-22, 2006.**

**39. Benter IF, Yousif MHM, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive tarts-treated with L-NAME. American Journal of Physiology Heart Circulatory Physiology 290(2):H684-9, 2006.**

**Publications ( cont.) 40. Benter IF, Yousif MHM, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. American Journal of Physiology Heart Circulatory Physiology 292(1):H666-72, 2007.**

**41. Al-Rashdan I, Canatan H, Al-Maghrebi M, Yousif MH, Khan SA, Benter IF. Cardioprotection from ischemia-reperfusion injury due to Ras-GTPase inhibition is attenuated by glibenclamide in the globally ischemic heart. Cell Biochemistry & Function 25: 455-61, 2007.**

**42. Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. Journal of Drug Targeting 15:83-8, 2007.**

**43. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity. Advanced Drug Delivery Reviews 30; 59:164-182, 2007.**

**44. Yousif MH, Kehinde EO, Benter IF. Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum. Pharmacological Research 56:209-216, 2007.**

**45.Yousif MH, Benter IF. Role of cytochrome P450 metabolites of arachidonic acid in regulation of corporal smooth muscle tone in diabetic and older rats. Vascular Pharmacology 47:281-287, 2007.**

**46. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. Journal of Clinical Investigation 117:3623-3632, 2007.**

**47. Yousif MHM, Akhtar S, Walther T, and Benter IF. Role of Ca2+/calmodulin-dependent protein kinase II in development of vascular dysfunction in diabetic rats with hypertension. Cell Biochemistry & Function 26:256-263, 2008.**

**48. Yousif MH, Benter IF, Abul AH, Abraham S, Walther T, Akhtar S. Inhibition of Ras-GTPase signaling by FPTIII ameliorates development of cardiovascular dysfunction in diabetic-hypertensive rats. Vascular Pharmacology 49:151-157, 2008.**

**49. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. American Journal of Nephrology 28:25-33, 2008.**

**50.Yousif MH, Benter IF, Roman RJ. Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Autonomic Autacoid Pharmacology 29: 33-41, 2009.**

**51.Al-Maghrebi M, Benter IF, Diz DI. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacological Research 59: 263-268, 2009.**

**52.Yousif MH, Benter IF, Dunn KM, Dahly-Vernon AJ, Akhtar S, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes. Autonomic Autacoid Pharmacology 29: 1-12, 2009.**

**53.Benter IF, Canatan H, Benboubetra M, Yousif MH, Akhtar S. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. Vascular Pharmacology 51:101-109, 2009.**

**Publications ( cont.) 54.Akhtar S, Almubrad T, Bron Aj, Yousif MH, Benter IF, Akhtar S. Role of epidermal growth factor receptor (EGFR) in corneal remodeling in diabetes. Acta Ophthalmol. 87(8):881-9, 2009.**

**55.Benter IF, Benboubetra M, Hollins AJ, Yousif MH, Canatan H, Akhtar S. Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vascular Pharmacology 51: 236-45, 2009.**

**56.Dhaunsi GS, Yousif MH, Benter IF. FPTIII Mitigates Peroxisome-Mediated Oxidative Stress in Kidneys of Spontaneously Hypertensive Diabetic Rats. Kidney Blood Press Res. 33(1):60-65, 2010.**

**57.Dhaunsi GS, Yousif MHM, Akhtar S, Chappell MC, Diz DI and Benter IF. Angiotensin-(1-7) Prevents Diabetes-Induced Attenuation in PPAR-γ and Catalase Activities. European Journal of Pharmacology, 638(1-3): 108-14, 2010.**

**58.Yousif MHM and Benter IF. Role of 20- hydroxyeicosa tetraenoic acid and epoxyeicosatrienoic acids in regulation of vascular function in a model of hypertension and endothelial dysfunction. Pharmacology, 86(3): 149-56, 2010.**

**59.Benter IF, Yousif MHM, Al-Saleh FM, Chappell MC and Diz DI. Angiotensin-(1-7) Blockade Attenuates Captopril- or Hydralazine-Induced Cardiovascular Protection in Spontaneously Hypertensive Rats-Treated with L-NAME. Journal of Cardiovascular Pharmacology, 57(5): 559-67, 2011.**

**60.Benter IF, Abul H, Al-Khaledi G, Canatan H, Akhtar S. Inhibition of Ras-GTPase farnesylation and the ubiquitin-proteasome-system or treatment with angiotensin-(1-7) attenuates spinal cord injury-induced cardiac dysfunction. Journal of Neurotrauma 28(7):1271-9, 2011.**

**61.El-Hashim AZ, Renno WM, Abduo HT, Benter IF. Effect of inhibition of the ubiquitin-proteasome-system and IκB kinase on airway inflammation and hyperresponsiveness in a murine model of asthma. Int J Immunopathol Pharmacol. 24(1):33-42, 2011.**

**62.Akhtar S, Yousif MH, Dhaunsi GS, Chandrasekhar B, Al-Farsi O, Benter IF. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. British Journal of Pharmacology 165(5): 1390-400, 2012.**

**63.El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF. Angiotensin 1-7 inhibits allergic inflammation, via the Mas receptor, through suppression of ERK1/2 and NF-κB dependent pathways. British Journal of Pharmacology 166(6):1964-76, 2012.**

**64.Yousif MH, Dhaunsi GS, Makki BM, Qabazard BA, Akhtar S, Benter IF. Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of Type-1 diabetes. Pharmacological Research 66(3):269-75, 2012.**

**65.Waleed Renno and Benter IF. Angiotensin-(1-7) via the Mas receptor alleviates the Diabetes-induced Decrease in GFAP and GAP-43 Immunoreactivity with Concomitant reduction in the COX-2 in Hippocampal Formation: An immunohistochemical study**

**Cellular and Molecular Neurobiology 2012.**

**Publications ( cont.) 66.Saghir Akhtar, Mariam H.M. Yousif, Ibrahim F. Benter. Activation of EGFR/erbB2 via pathways involving ERK1/2, p38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoS One 7(6):e39066, 2012.**

**67.** **Role of angiotensin II and angiotensin-(1-7) in diabetes-induced oxidative DNA damage in the corpus cavernosum.**

**Kilarkaje N, Yousif MH, El-Hashim AZ, Makki B, Akhtar S, Benter IF.**

**Fertil Steril. 100(1):226-33, 2013.**

**68.Benter IF, Al-Rashdan I, Yousif M, Akhtar S. Chronic treatment with LY294002, an inhibitor of phosphatidylinositol 3-kinase, attenuates diabetes-induced cardiac dysfunction in normotensive and hypertensive animals. Molecular & Cellular Biochemistry 373(1-2):259-64, 2013.**

**69.** **Akhtar S, Chandrasekhar B, Attur S, Yousif MH, Benter IF.**

**On the nanotoxicity of PAMAM dendrimers: Superfect® stimulates the EGFR-ERK1/2 signal transduction pathway via an oxidative stress-dependent mechanism in HEK-293 cells. International Journal of Pharmaceutics 448: 239–246, 2013.**

**70. Saghir Akhtar and Ibrahim Fadil Benter. The Role of Epidermal Growth Factor Receptor in Diabetes-Induced Cardiac Dysfunction. BioImpacts, 3(1): 5-9, 2013.**

**71. RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes. Benter IF, Babiker F. J Diabetes Res. 427693, 2013.**

**72. Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction. Akhtar S, Yousif MH, Attur S, Benter IF. PLoS One 8(6):e67813, 2013.**

**73. Chronic treatment with Ang-(1-7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes. Yousif MH, Makki B, El-Hashim AZ, Akhtar S, Benter IF. J Diabetes Res. 142154, 2014.**

**74. Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor. Akhtar S, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH, Benter IF. PLoS One 10(11):e0141657, 2015.**

**75. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes. Benter IF, Sarkhou F, Al-Khaldi AT, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH, Akhtar S. J Drug Target. 23(6):506-18, 2015.**

**76. Cationic Polyamidoamine Dendrimers as Modulators of EGFR Signaling In Vitro and In Vivo. Akhtar S, Al-Zaid B, El-Hashim AZ, Chandrasekhar B, Attur S, Yousif MH, Benter IF. PLoS One. 10(7):e0132215, 2015.**

**77. Endogenous angiotensin-(1-7)/Mas receptor/NO pathway mediates the cardioprotective effects of pacing postconditioning. Abwainy A, Babiker F, Akhtar S, Benter IF. American Journal of Physiology Heart Circ Physiol. 310(1):H104-12, 2016.**

**78. Naked Polyamidoamine Polymers Intrinsically Inhibit Angiotensin II-Mediated EGFR and ErbB2 Transactivation in a Dendrimer Generation- and Surface Chemistry-Dependent Manner. Akhtar S, El-Hashim AZ, Benter IF.**

**Molecular Pharmacology 13(5):1575-86, 2016.**

**79. Impact of PAMAM delivery systems on signal transduction pathways in vivo: Modulation of ERK1/2 and p38 MAP kinase signaling in the normal and diabetic kidney.**

**Akhtar S, Al-Zaid B, El-Hashim AZ, Benter IF.**

**Int J Pharm 514(2):353-363, 2016.**

**80. Angiotensin-(1-7) Downregulates Diabetes-Induced cGMP Phosphodiesterase Activation in Rat Corpus Cavernosum.**

**Dhaunsi GS, Yousif M, Makki B, Akhtar S, Benter IF.**

**Biomed Res Int. 5084961, 2017.**

**81. Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3Kδ/Akt and NFκB induction in a murine asthma model.**

**El-Hashim AZ, Khajah MA, Benter IF, Ezeamuzie C, Akhtar S.**

**Sci Rep. 7(1):9919, 2017.**

**82. Chronic administration of nano-sized PAMAM dendrimers in vivo inhibits EGFR-ERK1/2-ROCK signaling pathway and attenuates diabetes-induced vascular remodeling and dysfunction.**

**Akhtar S, Chandrasekhar B, Yousif MH, Renno W, Benter IF, El-Hashim AZ.**

**Nanomedicine. 18:78-89, 2019.**

**83. Ang-(1-7)/ MAS1 receptor axis inhibits allergic airway inflammation via blockade of Src-mediated EGFR transactivation in a murine model of asthma.**

**El-Hashim AZ, Khajah MA, Benter IF, Akhtar S.**

**PLoS One. 14(11):e0224163, 2019.**

**84. Nanotoxicology of Dendrimers in the Mammalian Heart: ex vivo and in vivo Administration of G6 PAMAM Nanoparticles Impairs Recovery of Cardiac Function Following Ischemia-Reperfusion Injury.**

**Babiker F, Benter IF, Akhtar S.**

 **Int J Nanomedicine. 2020;15:4393-4405.**

**85. Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety.**

**Akhtar S, Benter IF, Danjuma MI, Doi SAR, Hasan SS, Habib AM.**

 **J Drug Target. 2020: 1-35.**

**86.** [**The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications.**](https://pubmed.ncbi.nlm.nih.gov/34408653/)

**Shraim BA, Moursi MO, Benter IF, Habib AM, Akhtar S.**

**Front Pharmacol. 2021; 12:701390.**

**87.** [**Emerging innate biological properties of nano-drug delivery systems: A focus on PAMAM dendrimers and their clinical potential.**](https://pubmed.ncbi.nlm.nih.gov/34390777/)

**Kheraldine H, Rachid O, Habib AM, Al Moustafa AE, Benter IF, Akhtar S.**

**Adv Drug Deliv Rev. 2021; 178:113908.**

**88.** [**Mitigating Cardiotoxicity of Dendrimers: Angiotensin-(1-7) via Its Mas Receptor Ameliorates PAMAM-Induced Cardiac Dysfunction in the Isolated Mammalian Heart.**](https://pubmed.ncbi.nlm.nih.gov/36559167/)

**Akhtar S, Babiker F, Akhtar UA, Benter IF.**

**Pharmaceutics. 2022; 14(12):2673.**

**RU28318, an aldosterone antagonist in combination with an ACE inhibitor and/or angiotensin receptor blocker attenuates ischemia/reperfusion-induced cardiac dysfunction in diabetes.**

**In preparation.**

**Benter IF, Al-Rashdan I, Yousif M, Akhtar S. Treatment with chymostatin attenuates diabetes-induced cardiac dysfunction.**

**In preparation.**

**Benter IF, Al-Rashdan I, Yousif M, Akhtar S. Combined inhibition of Angiotensin Converting Enzyme and NADPH Oxidase prevents diabetes-induced cardiac dysfunction in hypertensive rats. In preparation.**

**Benter IF, Al-Rashdan I, Yousif M, Akhtar S. Treatment with angiotensin-(1-7) decreases diabetes-induced cardiac dysfunction-a comparison with Losartan and Captopril. In preparation.**

**Book Chapters**

1. **Benter IF, Juggi JS, Akhtar S.** Role of Ras/GTPase and calcium/calmodulin-dependent protein kinase II in the signal transduction mechanisms involved in hyperthermic preconditioning.

**Pathophysiology of Cardiovascular Disease, 2004**; 8, Pp. 101-107 edited by N.S. Dhalla, H. Rupp, A. Angel & G.N. Pierce, Kluwer Academic Publishers, Boston, U.S.A.

1. **Benter IF, Yousif M, Juggi JS, Akhtar S.** The Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas receptor axis: A potential target for treating diabetic cardiovascular disease. **Mechanisms of Cardiovascular Dysfunction in Diabetes, 2013,** edited by B.Turan and NS Dhalla, Springer, New York, USA.

**CITATIONS**

**Publications of Ibrahim Benter have been cited more than six**

**thousand ( 6000+ ) times, (H-index=40).**

Abstracts **1.Stier C.T. and Benter I.F.: Thromboxane in severe hypertension in stroke-prone spontaneously hypertensive rats (SHRSP). The Pharmacologist 28: 153, 1987.**

**2.Stier C.T. and Benter I.F.: Combined inhibition of thromboxane synthase and converting enzyme in stroke-prone hypertensive rats (SHRSP). Kidney International 31: 310, 1987.**

**3.Stier C.T., Benter I.F., Itskovitz H.D. and Roethel S.: Preservation of kidney function and increased survival in stroke-prone spontaneously hypertensive rats (SHRSP). Fed. Proc, 46: 1290, 1987.**

**4.Benter I.F. and Ward P.E.: Degradation of opioid peptides by human cerebrospinal fluid aminopeptidase activity. Faseb J. 3: A731, 1989.**

**5.Benter I.F., Wilk S., Dick L and Ward P.E.: Metabolism of vasoactive peptides by plasma and purified renal aminopeptidase. M. Faseb J. 4: A991, 1990.**

**6.Benter I.F., Diz D.I. and Ferrario C.M.: Angiotensin-(1-7) is vasoactive in the circulation of areflexic Sprague-Dawley rats. Faseb J. 6: A1735, 1992.**

**ABSTRACTS (cont.) 7.Benter I.F., Diz D.I. and Ferrario C.M.: Chronic intravenous Angiotensin-(1-7) infusions activate antihypertensive mechanisms in the spontaneously hypertensive rats. Amer. J. Hypertension, 1993.**

**8.Diz D.I., Fantz D.L., Benter I.F. and Bosch S.M.: Substance P antagonist blocks the cardiovascular effects of Angiotensin II in the rat nucleus tractus solitarii. Hypertension :25 {No. 6} P. 1360, 1995.**

**9.Benter I.F., Diz D.I. and Ferrario C.M.: -Adenergic and Angiotensin II pressor responses are reduced in Angiotensin-(1-7) treated spontaneously hypertensive rats. Hypertension:25 {No. 6} P. 1416, 1995.**

**10.Muthalif M.M., Benter I.F. and Malik K.U.: Cytosolic phospholipase A2 (cpla2) and MAP- cam kinases are involved in norepinephrine (NE) simulated arachidonic acid (AA) release and prostanoid synthesis in rabbit aortic smooth muscle cells (RASMC): an antisense approach. Messengers/Phosphoproteins, p.26, 1995.**

**11.Malik K.U., Muthalif M.M., Benter I.F. and Al-Sibai W.: Ca2+/cam-Dependent protein kinase II (camk II) mediates activation of MAP kinase (MAPK) and cytosolic phospholipase A2(cpla2) in norepinephrine (NE) induced arachidonic acid (AA) release in rabbit vascula smooth muscle cells (VSMC). Faseb Journal, Vol:10, No:3, A23, 1996.**

**12.Muthalif M.M., Benter I.F., Uddin M.R. and Malik K.U.: Signal transduction mechanisms involved in Angiotensin-(1-7) {Ang-(1-7)} stimulated arachidonic acid (AA) release and prostanoid synthesis (PG) in rabbit vascular smooth muscle cells (VSMC). Faseb Journal, Vol:10, No:3, A162, 1996.**

**13.Benter I.F., Ayubi M.A. and Ward P.E.: Enkephalin metabolism by human plasma and endothelium. Faseb Journal, Vol:10, No:3, A413, 1996.**

**14.Malik, K.U., Benter I.F., Uddin M.R. and Muthalif, M.M.: Signal transduction mechanism of alpha-adrenergic receptor stimulated prostaglandin synthesis in vascular smooth muscle cells. VT World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, Argentina, p. 64,August 1996.**

**ABSTRACTS (cont.) 15.Benter I.F.: Mechanism involved in Angiotensin (Ang) 1-7 and II stimulated arachidonic acid (AA) release and prostanoid synthesis (PG) in rabbit vascular smooth muscle cells (VSMC). Microcirculation, Vol. 4 (1):183, 1997.**

**16.Mubarack M.M., Benter I.F.: Contribution of phospholipase D (PLD) in Norepinephrine (NE) stimulated arachidonic acid (AA) release and prostacyclin (PG) Synthesis in rabbit vascular smooth muscle cells (VSMC). Microcirculation, Vol. 4 (1):183, 1997.**

**17.Muthalif M.M., Karzoun N., Benter I.F., Harper J., Uddin M.R., and Malik K.U.: Mechanism of cam kinase II (camkii) mediated MAP kinase (MAPK) activation by norepinephrine (NE) in vascular smooth muscle cells (VSMC). Involvement of cytochrome P-450 (CYP-450) and lipoxygenase (LO) metabolites of arachidonic acid (AA). Faseb Journal, Vol: 12, No: 4, March, 1998.**

**18.Diz D.I., Benter I.F., Bosch S.M., and Ferrario C.M.: Angiotensin-(1-7) infusion attenuates angiotensin II - induced prostacyclin release from kidney slices. Amer. J. Hypertension, Vol. 11, No: 4, Part 2, p. 32A, April, 1998.**

**19.Benter I.F., Mutalif M.M., Karzoun N., Malik S.F., and Malik K.U.: Contribution of Ras gtpase to the Development of Angiotensin II-Induced Hypertension. FASEB, 1999.**

**20.Muthalif M.M., Harper J., Karzoun N., Benter I.F., Dress M., and Malik K.U.: Cytosolic Phospholipase A2 (cpla2) is phosphorylated and activated by Ca2+/calmodulin-dependent protein kinase II (cam kinase II). FASEB, 1999.**

**21.Muthalif M.M., Karzoun N., Benter I.F., and Malik K.U.: Functional significance of calcium/calmodulin dependent protein kinase II in angiotensin II-induced vascular hyperplasia and hypertension. Hypertension, 2001.**

**22. Benter I.F., and C.W.T. Pilcher: Pressor sensitivity is altered in deoxycorticosterone salt-induced hypertension (Role of Ras/gtpase/MAP Kinase Pathway). Seventh Annual Health Sciences Poster Day, Faculty of Medicine, Kuwait University, April, 2002.**

**22.M.H.M. Yousif, I. F. Benter and C.W.T. Pilcher:**

**Inhibition of rasgtpase/MAP kinase pathway improves vasorelaxation due to isoprenaline in mesenteric vascular bed of hypertensive animals. Seventh Annual Health Sciences Poster Day, Faculty of Medicine, Kuwait University, April, 2002.**

**23. I. F. Benter, M.H.M. Yousif and C.W.T. Pilcher: 20-hydroxyecoisatetraneoic acid contributes to increased vascular reactivity to norepinephrine in L-NAME-induced hypertension. Seventh Annual Health Sciences Poster Day, Faculty of Medicine, Kuwait University, April, 2002.**

**24. S. Mustafa, I. F. Benter and C.W.T. Pilcher: Metabolites of arachidonic acid and Ras are responsible for altered vascular reactivity of the aorta in hypertension. Seventh Annual Health Sciences Poster Day, Faculty of Medicine, Kuwait University, April, 2002.**

**25. M. H. Yousif, I.F Benter, S. Abraham and S. Akhtar: Tyrosine Kinases (TKS) and Cytochrome P-450 (CYP-450) metabolites of arachidonic acid (AA) contribute to the development of hypersensitivity to endothein-1 in diabetic rats. British Pharmacological Society, 2002.**

**ABSTRACTS (cont.) 26. M.H. Yousif , I.F. Benter and S. Akhtar: Inhibition of Calcium/calmodulin-dependent protein kinase II (camkii) normalizes diabetics-induced abnormal vascular reactivity in the rat perfused mesentric vascular bed, British Pharmacological Society, 2002.**

**27. Benter, I.F., Juggi, J.S, Chronic inhibition of nitric oxide synthesis worsens recovery from global ischemia in hypertensive rats-Role of small G-protein Ras. Journal of Molecular and Cellular Cardiology, Volume 34, 2002.**

**28. Benter, I.F., Khan, I., Juggi, J.S, Inhibition of Ras/gtpase prevents elevation of ventricular sodium/hydrogen exchanger-1 levels and improves recovery from ischemia in hypertensive rats. Journal of Molecular and Cellular Cardiology, Volume 34, 2002.**

**29. Juggi, J.S., Benter, I.F, Calcium/calmodulin-dependent protein kinase II plays a significant role in mediating the beneficial effects of ischemic preconditioning on cardiac function during recovery from global ischemia. Journal of Molecular and Cellular Cardiology, Volume 34, 2002.**

**30. Akhtar, S., and Benter, IF. Contribution of Ras gtpase/MAP kinase Pathway to Angiotensin II- and deoxycorticosterone-salt-induced hypertension. Journal of Pharmacy and Pharmacology, 54, S-103-104, 2002.**

**31. Yousif, M.H., Akhtar, S., and Benter, I.F. Tyrosine kinases (tks) and cytochrome P-450 (CYP-450) metabolites of arachidonic acid (AA) play a role in development of cardiovascular dysfunction in diabetes. Journal of Pharmacy and Pharmacology, 54, S-103, 2002.**

**32. Akhtar, S., Benter, I.F., and Juggi, J.S., Calcium/calmodulin-dependent protein kinase II (camk II) and Receptor Tyrosine Kinases (rtks) have a beneficial role whereas Ras/gtpase has a detrimental effect on recovery of cardiac function after global ischemia. Journal of Pharmacy and Pharmacology, 54, S-101-102, 2002.**

**33. Akhtar S. And Benter, I.F. Contribution of Ras gtpase/MAP Kinase Pathway to Angiotensin II–and Deoxycorticosterone-salt-induced Hypertension. Journal of Pharmacy and Pharmacology, 54, S-103-104, 2002.**

**34. Yousif, M.H., Akhtar, S. And Benter, I.F. Tyrosine Kinases (tks) and cytochrome P-450 (CYP-450) metabolites of arachidonic acid (AA) play a role in development of Cardiovascular dysfunction in diabetes. Journal of Pharmacy and Pharmacology, 54, S-103, 2002.**

**ABSTRACTS (cont.) 35. Akhtar, S., Benter, I.F. and Juggi, J.S.: Calcium/calmodulin-dependent protein kinase II (camk II) and Receptor Tyrosine Kinases (rtks) have a beneficial role whereas Ras/gtpase has a detrimental effect on recovery of cardiac function after global ischemia. Journal of Pharmacy and Pharmacology, 54, S-101-102, 2002.**

**36. Benter IF, Yousif MH, Akhtar - S Inhibition of Calcium/calmodulin-dependent protein kinase II (camkii) normalizes diabetics-induced abnormal vascular reactivity in the rat perfused mesentric vascular bed, Eighth Annual Health Sciences Poster Day, Faculty of Medicine, Kuwait University, 2003.**

**37. Benter IF, Juggi JS, Akhtar - S Tyrosine kinases (tks) have a Beneficial Role on Recovery of Cardiac Function after Global Ischemia. Eighth Annual Health Sciences Poster Day, Faculty of Medicine, Kuwait University, April 21-23, 2003.**

 **38. Yousif MH, Benter IF, Abraham S, Akhtar S - Cytochrome (CYP-450) Metabolites of Arachidonic Acid (AA) Contribute to the Development of Hypersensitivity to Endothelin-1 in Diabetic Rats. Eighth Annual Health Sciences Poster Day, Faculty of Medicine, Kuwait University, April 21-23, 2003.**

**39. Yousif MH, Benter IF, Cherian A, Akhtar S - Tyrosine Kinases (TKS) Play a Role in Development of Cardiovascular Dysfunction in Diabetes. Eighth Annual Health Sciences Poster Day, Faculty of Medicine, Kuwait University, April 21-23, 2003.**

**40. Akhtar, S., Benter, I.F., and Juggi, J.S., Sustained delivery of a Ras inhibitor improves recovery of cardiac function in the globally ischemic heart. Abstract Proceed. Intern. Symp. Control. Rel. Bioact. Mater. Res 30 (abstr. 733), 2003.**

**41. Benboubetra, M., Yousif, M.H., Benter, I.F., and Akhtar, S. Epidermal growth factor receptor tyrosine kinase plays an important role in the development of cardiovascular dysfunction in diabetes. Journal of Pharmacy and Pharmacology, 55: S-90 (Abstract no. 216), 2003.**

**42. Akhtar, S., Benter, I.F. and Juggi, J.S. - Sustained delivery of a Ras inhibitor improves recovery of cardiac function in the globally ischemic heart. Abstract Proceed. Intern. Symp. Control. Rel. Bioact. Mater. Res 30, (Abstract no. 733), 2003.**

**43. Benboubetra, M., Yousif, M.H., Benter, I.F. and Akhtar, S.**

**Epidermal growth factor receptor tyrosine kinase plays an important role in the development of cardiovascular dysfunction in diabetes. Journal of Pharmacy and Pharmacology, 55: S-90 (Abstract no. 216), 2003.**

**44. Benboubetra, M., Omidi, Y., Yousif, M., Griffiths, S., Benter, I., and Akhtar, S. - Microarray-based gene expression profiling in streptozotocin-induced diabetes: role of receptor tyrosine kinases in vascular dysfunction.Proceed Intern Symp Control Rel Bioact Mater Res 31, (Abstract no. 38), 2004.**

**45. Benter IF, Yousif MHM, Juggi JS. - Inhibition of Ras-gtpase or tyrosine kinases but not epidermal growth factor receptor improves recovery of cardiac function in the globally ischemic heart of the diabetic rat. Ninth Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 19-21, (Abstract no. 212), 2004.**

**46. Hares NG, Oommen KE, Yousif MHM, Benter IF. Inhibition of Phosphoinositide 3-kinase protects the carotid artery against diabetes-induced vascular dysfunction. Ninth Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 19-21, (Abstract no. 216), 2004.**

**47. Yousif MHM, Benter IF, Abraham S, Cherian A. Signal transduction through Ras-GTPase contributes to development of diabetes-induced abnormal vascular reactivity in the rat perfused mesenteric vascular bed. Ninth Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 19-21, (Abstract no. 222), 2004.**

**48. Hares NG, Cherian A, Yousif MHM, Benter IF. - Inhibition of phosphoinositide 3-kinase prevents diabetes-induced vascular dysfunction in the perfused mesenteric vascular bed. Tenth Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no. 213), 2005.**

**49. Benter IF, Yousif MHM, Anim JT, Juggi JS, Hoteit LJ, Abraham S. - Angiotensin-(1-7) attenuates development of hypertension and end-organ damage in spontaneously hypertensive rats with chronic nitric oxide synthesis inhibition. Tenth Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no. 214), 2005.**

**50. Canatan H, Benter IF, Yousif MHM, Akhtar S. - Microarray-based gene expression profiling in diabetes: role of receptor tyrosine kinases in vascular dysfunction. Tenth Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no. 217), 2005.**

**ABSTRACTS (cont.) 51. Yousif MHM, Benter IF, Abraham S, Oommen E, Akhtar S.**

**The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery.**

**Tenth Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no. 218), 2005.**

**52. Griffiths SM, Yousif MH, Benter If, Hollins AJ, and Akhtar S.**

**The effect of hyperglycaemia on EGFR signalling and its potential role in diabetes-induced vascular dysfunction. Journal of Pharmacy and Pharmacology, 57, S-37 (Abstract no. 059), 2005.**

**53. Benter IF, Yousif MHM, Anim JT, Cojocel C, Diz DI. - Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats- treated with L-NAME. 59th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research in association with the Council on the Kidney in Cardiovascular Disease. American Heart Association. USA, 2005.**

**54. Dhaunsi GS, Yousif MH, Alsaeid M, Benter IF. - Diabetes-induced activation of peroxisomal functions in kidneys of spontaneously hypertensive rats if Ras-gtpase-mediated.**

**Eleventh Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no. 20), 2006.**

**55.Yousif MH, Benter IF, Abraham S, Cherian A, Oommen E, Canatan H. - Inhibition of Ca2+/calmodulin-dependent protein kinase II, Ras-gtpase and 20-hydroxyeicosatetraenoic acid attenuate the development of diabetes-induced vascular dysfunction in the rat carotid.Eleventh Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no. 213), 2006.**

**56. Al-Saleh FM, Al-Maghrebi M, Benter IF. - Angiotensin (1-7) contributes to captopril-induced cardiac protection in L-NAME-treated SHR. Eleventh Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no. 214), 2006.**

**57. Juggi JS, Canatan H, Al-Maghrebi M, Joseph S, Bitar MS, Benter IF - FPTIII improves cardiac recovery by inhibiting farnesylation of Ras-gtpase and activation of mitochondrial ATP-sensitive potassium channels.Eleventh Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no. 233), 2006.**

**58.Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI -**

**Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. 60th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research in association with the Council on Kidney in Cardiovascular Disease, U.S.A., September 2006.**

**ABSTRACTS (cont.) 59.Hares NG, Abraham S, Cherian A, Oomen E, Yousif MH, Benter IF - Phosphoinositide 3-kinase inhibition prevents diabetes-induced vascular dysfunction in the perfused mesenteric vascular bed. International Diabetes Conference. Global Aspects of Diabetes: Shaping the Future. (Abstract no: 18), Oct 30-Nov 2, 2006.**

**60.Yousif MH, Benter IF, Abraham S, Cherian A, Oommen E, Canatan H. - Inhibition of Ca2+/calmodulin-dependent protein kinase II, RAS-gtpase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery. International Diabetes Conference. Global Aspects of Diabetes: Shaping the Future. (Abstract no: 21), Oct 30-Nov 2, 2006.**

**61.Dhaunsi GS, Yousif MH, Alsaeid M, Cojocel C, Benter IF -**

**Ras-gtpase regulates diabetes-induced activation of peroxisomal functions in kidneys of spontaneously hypertensive rats.**

**International Diabetes Conference. Global Aspects of Diabetes: Shaping the Future. (Abstract no: 23), Oct 30-Nov 2, 2006.**

 **62.Canatan H, Benter IF, Yousif MHM, Akhtar S. - Microarray-based gene expression profiling in diabetes: potential role of receptor tyrosine kinases in vascular dysfunction. International Diabetes Conference. Global Aspects of Diabetes: Shaping the Future. (Abstract no: 22), Oct 30-Nov 2, 2006.**

**63.Benter I, Yousif MH, Cojocel C. Al-Maghrebi M and Diz DI. -**

**Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Renal vascular dysfunction in diabetic hypertensive rats. International Diabetes Conference. Global Aspects of Diabetes: Shaping the Future. (Abstract no: 19), Oct 30-Nov 2, 2006.**

**64.Benter I, Yousif MH Juggi JS - Role of Ras-gtpase, tyrosine kinases and epidermal growth factor receptor in recovery of cardiac function in the globally ischemic heart of the diabetic rat.**

**International Diabetes Conference. Global Aspects of Diabetes: Shaping the Future. (Abstract no: 20), Oct 30-Nov 2, 2006.**

**65.Yousif MHM, Cojocel C, Al-Maghrebi M, Abraham S, Oomen E, Cherian A and Benter IF - Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Twelfth Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no: 200), April 16-18, 2007.**

**66. Dhaunsi GS, Benter IF, Yousif MHM, Kaur J and Cojocel C -**

**Effect of apocynin and FPTIII on NADPH oxidase system in kidneys of STZ-treated spontaneously hypertensive rats. Twelfth Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, (Abstract no: 199) April 16-18, 2007.**

**67. Benter IF, Yousif MH, Cojocel C., Al-Saleh F, Al-Maghrebi M, and Diz D. - Angiotensin-(1-7) prevents renal vascular dysfunction in diabetic hypertensive rats. High Blood Pressure Research in association with the Council on the Kidney in Cardiovascular Disease. American Heart Association. USA; May, 2007.**

**68. Yousif MH, Benter IF, Diz D and Chapplle M. - Evidence that multiple receptor subtypes mediate angiotensin-(1-7) dependent vasodilation of the rat renal artery. High Blood Pressure Research in association with the Council on the Kidney in Cardiovascular Disease. American Heart Association. Arizona, USA; October, 2007.**

**69. Benter IF, Canatan H, Yousif MHM, Anim JT, Akhtar S. -**

**Micro-array based transcriptome analysis reveals global gene upregulation associated with kidney damage in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor and rasgtpase. 13th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 22-24, Abstract no. 187. [Award Winner], 2008.**

**70. Benter IF, Dhaunsi GS, Yousif MHM. - Angiotensin-(1-7) modulates PPAR-γ in kidneys of diabetic spontaneously hypertensive rats: role of peroxisomes. 13th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 22-24, Abstract no. 188, 2008.**

**ABSTRACTS (cont.) 71. Yousif MHM, Benter IF, Dhaunsi GS, Abraham S, Cherian A, Oommen E. - Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. 13th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 22-24, Abstract no. 194, 2008.**

**72. Makki B, Benter IF, Dhaunsi GS. - Prostaglandins contribute to the cardioprotective effect of Angiotensin-(1-7) in diabetes. 13th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 22-24, Abstract no. 189, 2008.**

 **73. Makki B, Benter IF. - Role of Angiotensin-(1-7) in mediating the cardioprotective effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. 13th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 22-24, Abstract no. 190, 2008.**

**74. Akhtar S, Benter IF, Hollins AJ, Omidi Y. - Toxicogenomics of cationic delivery systems: the influence of polymer architecture on genocompatibility and sirna-mediated gene silencing. 13th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 22-24, Abstract no. 199, 2008.**

**75. Benter IF, Canatan H, Yousif MHM, Anim JT, Akhtar S. - Micro-array based transcriptome analysis reveals global gene upregulation associated with kidney damage in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor and rasgtpase. The 2nd Kuwait International Pharmaceutical Conference (KIPC), Faculty of Pharmacy, Kuwait University, April 22-24, (2009). Abstract no: 32.**

**76. Yousif MH, Roman R, Varughese S, Abraham S, Benter IF. - Role of cytochrome P-450 metabolites of arachidonic acid in the enhanced cardiac dysfunction in diabetic rats following ischemic reperfusion injury. 14th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 21-23, (2009). Abstract no: 166.**

**77. Abul AH, Yousif MH, Cherian A, Ommen E, Benter IF. -Characterization of angiotensin-(1-7)-induced relaxation in the rat corpus cavernosum. 14th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 21-23, (2009). Abstract no: 159.**

**78. Yousif MH, Abraham S, Cherian A, Ommen E, Benter IF. -Angiotensin-(1-7) produces vasodilation of the rat renal artery. 14th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 21-23, (2009). Abstract no: 165.**

**79. Renno WM, Al-Banaw AG, George P, Abu-Ghefreh AA, Benter IF, Yousif MH, Akhtar S. - Angiotensin-(1-7) prevents the diabetes-induced decrease in astrocyte GFAP immunoreactivity in hippocampal formation. 14th Annual Health Sciences Poster Conference, Faculty of Medicine, Kuwait University, April 21-23, (2009). Abstract no: 6.**

**80**. **Al-Farsi OA, Yousif MH, Benter IF, Akhtar S. Does Angiotensin-(1-7) inhibit the development of diabetes-induced vascular dysfunction by inhibiting epidermal growth factor receptor signaling? 15th Health Sciences Poster Conference, Health Sciences Centre, Kuwait University, April 20-22, (2010). Abstract no: 184.**

**81. Yousif MH, Akhtar S, Benter IF. Inhibition of phosphatidyl inositol 3-kinase produces cardiovascular protection in a model of diabetes and hypertension. 15th Health Sciences Poster Conference, Health Sciences Centre, Kuwait University, April 20-22, (2010). Abstract no: 190.**

**82. Benter IF, Yousif MH, Al-Saleh FM, Raghupathy R, Chappell MC, Diz DI. 'Angiotensin-(1-7) Blockade Attenuates Captopril- or Hydralazine-Induced Cardiovascular Protection in Spontaneously Hypertensive Rats-Treated with L- NAME'. The 2nd Kuwait Medica Conference & Exhibition, Vice President Office. 11-13 April, 2011, Kuwait International Fair Ground Hall, Mishref, Kuwait.**

**83. 1. Al- Sumairi A, Akhtar S, Benter IF. Combined inhibition of angiotensin converting enzyme and NADPH oxidase prevents diabetes-induced cardiac Dysfunction. 17th Health Science Poster Conference, Health science Centre, Kuwait University May 8-10, (2012). Abstract no: 165.**

**84. Al-Turki A, Benter IF. Levosemindan improves cardiac recovery from ischemia in diabetic and/or hypertensive rat models. 17th Health Science Poster Conference, Health science Centre, Kuwait University May 8-10, (2012). Abstract no: 166.**

**85. Narayana K, Yousif MHM, Makki B, Akhtar S, Benter IF. Angiotensin-(1-7) abrogates oxidative DNA damage in corpus cavernosum of type 1 diabetic rats. 17th Health Science Poster Conference, Health science Centre, Kuwait University May 8-10, (2012). Abstract no: 172.**

**86. Varghese S, Chandrasekhar B, Attur S, Benter IF, Akhtar S. Activation of epidermal growth factor receptor enhance the cardio protective effects of Losartan in diabetes. 17th Health Science Poster Conference, Health science Centre, Kuwait University May 8-10, (2012). Abstract no: 176.**

**87. Yousif MHM, Benter IF, Makki B, Cherian A, Akhtar S. Chronic treatment with angiotensin-(1-7) corrects diabetes-induced erectile dysfunction. 17th Health Science Poster Conference, Health science Centre, Kuwait University May 8-10, (2012). Abstract no: 177.**

**88. El Hashim AZ, Renno WM, Abduo HT, Jaffal SM, Akhtar S, Benter IF. Effect of inhibition of the ubiquitin- proteasome-system and IkappaB kinase on airway inflammation and hyperresponsiveness in a murine model of asthma. 17th Health Science Poster Conference, Health science Centre, Kuwait University May 8-10, (2012). Abstract no: 182.**

**89.** **Akhtar S and Benter IF. Superfect polyamidoamine delivery system modulates EGFR signal transduction. Fourth Kuwait International Pharmacy Conference, Kuwait, 2013.**

**90. Akhtar S and Benter IF. Activation of erbB2 and downstream signaling via Rho kinase mediates diabetes-induced vascular dysfunction. 18th Health Science Poster Conference, Health science Centre, Kuwait University May 8-10, (2013).**